{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:56:50Z","timestamp":1759334210911,"version":"build-2065373602"},"reference-count":3,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: La urticaria cr\u00f3nica espont\u00e1nea se caracteriza por aparici\u00f3n diaria de habones y\/o angioedema (Fig.1) sin desencadenante espec\u00edfico, durante m\u00e1s de 6 semanas. El tratamiento se basa en antihistam\u00ednicos H1 de segunda generaci\u00f3n y en pacientes\u00a0 con respuesta insuficiente la terapia con Omalizumab ha sido eficaz1, sin embargo es un tratamiento costoso y a largo plazo. La WAO (por sus siglas en ingl\u00e9s, World Allergy Organization) ha propuesto un esquema de descenso al alcanzar la remisi\u00f3n completa.\nReporte de caso: Femenino de 66 a\u00f1os, enviada a valoraci\u00f3n por habones generalizados de 6 a\u00f1os de evoluci\u00f3n en tratamiento con fexofenadina 180mg, con respuesta parcial. Se inician antihistam\u00ednicos H1 a dosis triple, sin mejor\u00eda, manteniendo UCT (por sus siglas en ingl\u00e9s, Urticaria Control Test) en 5 puntos por lo que se agrega Omalizumab 300mg cada 4 semanas, con adecuada respuesta cl\u00ednica. Ante la remisi\u00f3n completa, en noviembre 2023 se inici\u00f3 el descenso de Omalizumab de acuerdo a protocolo de la WAO (Fig.2), en marzo 2025 se aplic\u00f3 la \u00faltima dosis.\nConclusi\u00f3n: Se presenta el caso de una paciente con urticaria cr\u00f3nica espont\u00e1nea, donde tras alcanzar la remisi\u00f3n completa con Omalizumab se implementa el protocolo de descenso propuesto por la WAO, periodo en que nuestra paciente permaneci\u00f3 asintom\u00e1tica, con puntajes de UCT superiores a 13 permitiendo reducir progresivamente el uso de antihistam\u00ednicos. El protocolo de descenso de Omalizumab en el tratamiento de urticaria cr\u00f3nica espont\u00e1nea es seguro, eficaz, disminuye el riesgo de reactivaci\u00f3n de la enfermedad y evita prolongar el tratamiento.\nPalabras clave:\u00a0Antihistam\u00ednico, descenso gradual, omalizumab, UCT, Urticaria cr\u00f3nica.<\/jats:p>","DOI":"10.29262\/ram.v72i3.1520","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:23:25Z","timestamp":1759242205000},"page":"231","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Protocolo de retiro de Omalizumab en Urticaria cr\u00f3nica espont\u00e1nea: Caso cl\u00ednico&lt;\/b&gt;","&lt;b&gt;Omalizumab Withdrawal Protocol for Chronic Spontaneous Urticaria: Clinical Case&lt;\/b&gt;"],"prefix":"10.29262","volume":"72","author":[{"given":"Daniela","family":"Ramirez Vazquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystopherson Gengyny","family":"Caballero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A\u00edda In\u00e9s","family":"L\u00f3pez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rivero Yeverino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jes\u00fas","family":"R\u00edos L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Sergio","family":"Papaqui Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahnisi","family":"Riley P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"62734","unstructured":"1. Grupo de trabajo de la Gu\u00eda Mexicana para el Diagn\u00f3stico y el Tratamiento de la Urticaria. (2014). Gu\u00eda Mexicana para el Diagn\u00f3stico y el Tratamiento de la Urticaria. Revista Alergia M\u00e9xico, 61(Supl. 2), S117\u2013S193."},{"key":"62735","unstructured":"2. Wesley, A., Holgate, S., & O'Hehir, R. (2020). Urticaria and angioedema. En Middleton's Allergy: Principles and Practice(9.a ed., pp. 562\u2013571). Elsevier."},{"key":"62736","doi-asserted-by":"crossref","unstructured":"3. Maoz-Segal, R., Levenberg, G., Levy, T., Offengenden, I., Iancovich-Kidon, M., Agmon-Levin, N., & Agmon-Levin, N. (2024). Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels. World Allergy Organization Journal, 17(4), 100905.","DOI":"10.1016\/j.waojou.2024.100905"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1520\/2767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1520\/2767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:23:28Z","timestamp":1759242208000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":3,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v72i3.1520","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"type":"electronic","value":"2448-9190"},{"type":"print","value":"0002-5151"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}